Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review

    April 2023 in “ JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology ”
    Andrea Sechi, J Song, Massimo Dell'Antonia … Luigi Naldi
    Studysummary This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 35

    1. The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies Frontiers in pharmacology · 2022
    2. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study Frontiers in Medicine · 2022
    3. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    4. A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib JAAD case reports · 2022
    5. Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial Journal of the American Academy of Dermatology · 2021
    6. Oral Tofacitinib for the Treatment of Alopecia Areata in Pediatric Patients Pediatric Dermatology · 2021
    7. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    8. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    9. A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021
    10. Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair British Journal of Dermatology · 2021
    11. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    12. Alopecia Areata Flare Patterns in Children and Young Adults on Systemic Tofacitinib Journal of the American Academy of Dermatology · 2021
    13. Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses Journal of Cosmetic Dermatology · 2021
    14. Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study Pediatric Dermatology · 2020
    15. Low-Dose Tofacitinib for Treating Patients with Severe Alopecia Areata: An Efficient and Cost-Saving Regimen European Journal of Dermatology · 2019
    16. Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata Dermatologic Therapy · 2019
    17. Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata Journal of The American Academy of Dermatology · 2019
    18. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    19. Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients Dermatologic Therapy · 2019
    20. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    21. JAK Inhibitors for Treatment of Alopecia Areata ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2018
    22. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    23. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    24. Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
    25. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    26. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
    27. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    28. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    29. Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
    30. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    31. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
    32. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    33. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    34. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    35. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015

    Related research 4

    1. Resistant Alopecia Areata Treated with Tofacitinib International Journal of Trichology · 2022
    2. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
    3. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    4. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016